Tafluprost acid
Code | Size | Price |
---|
TAR-T20142-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Tafluprost acid is a selective agonist at the prostaglandin F receptor.
CAS:
209860-88-8
Formula:
C22H28F2O5
Molecular Weight:
410.458
Purity:
0.98
SMILES:
O[C@H]1C[C@@H](O)[C@H](C=CC(F)(F)COc2ccccc2)[C@H]1CC=C/CCCC(O)=O
References
1. Krupa M, Chody?ski M, Ostaszewska A, Cmoch P, Dams I. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost. Molecules. 2017 Jan 31;22(2). pii: E217. doi: 10.3390/molecules22020217. PubMed PMID: 28146132.
2. Fuwa M, Ueda K, Akaishi T, Yamashita N, Kirihara T, Shimazaki A, Mano H, Kawazu K. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. PLoS One. 2016 Jul 6;11(7):e0158797. doi: 10.1371/journal.pone.0158797. eCollection 2016. PubMed PMID: 27383260; PubMed Central PMCID: PMC4934872.
3. Kaarniranta K, Ik?heimo K, Mannermaa E, Ropo A. Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Clin Pharmacokinet. 2016 Apr;55(4):485-94. doi: 10.1007/s40262-015-0331-x. PubMed PMID: 26391697.
4. Akaishi T, Shimazaki A, Tonouchi A, Ueda K, Miyawaki N, Kawazu K. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models. J Ocul Pharmacol Ther. 2015 Nov;31(9):518-24. doi: 10.1089/jop.2015.0031. Epub 2015 Sep 1. PubMed PMID: 26325164.